All News

psor.elb_.jpg

TNF Inhibitor and Biologic Induced Psoriasis

d Jack Cush, MD

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Read Article
johns.hopkins.jpg

Top Rheumatology Centers Led by Johns Hopkins

d Jack Cush, MD

Medscape has reported the results of the US News & World Report's annual ranking of the best adult rheumatology hospitals nationwide has again honored Johns Hopkins Hospital, with runner up status going to the Cleveland Clinic, Hospital for Special Surgery, NewYork-Presbyterian Unive

Read Article
PSA2L.jpg

Joint Surgery Rates Remain High in Psoriatic Arthritis

d RheumNow

The incidence rate of joint surgery among patients with psoriatic arthritis (PsA) has remained persistently high, double that of the general population, according to a new Danish cohort study.

Read Article
WAR.RA_.jpg

War on RA - Part 2: It's All About You

d Jack Cush, MD

Part II of this series is a direct message to rheumatologists. If we’re doing such a great job in RA, then why do we need a war on RA? Why is this conflict being laid at the feet of good soldier rheumatologists, those who toil daily at winning therapeutic battles one patient at a time? The reasons are blunt and true.

Read Article
PSS.hands_.Raynauds.jpg (keep)

Abatacept Disappoints in Systemic Sclerosis

d Jack Cush, MD

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

Read Article
A prospective 10-year study of 1,024 older women shows that severe abdominal aortic calcification (AAC) scores were associated with ncreased fracture risk (HR 1.48 [1.15-1.91], p=0.002; not fully indicated by predictors of bone structure. https://t.co/NVbo9eHcYF

Links:

Dr. John Cush RheumNow ( View Tweet)

Observational study of 124 gouty patients with high cholesterol & triglycerides treated with ULT (febuxostat, allopurinol, benzbromarone) showed that ULT significantly lowered SUA and lipid levels too. https://t.co/JSdh3TRTX3

Links:

Dr. John Cush RheumNow ( View Tweet)

NHANES analysis shows that higher serum uric acid (SUA) levels had a greater risk of coronary heart disease and stroke mortality (mainly women >50 years); but there was no link between SUA and all-cause and cancer mortality. https://t.co/UGNSiKsjQl

Links:

Dr. John Cush RheumNow ( View Tweet)

The War on RA - is being fought daily by rheumatologists - Change, Innovation and Discovery will be driven by Rheumatologists if we are to win this war. This is the 2nd of a series on the immense challenge of #RA today. We need you! https://t.co/7vOzRvvuVi

Links:

Dr. John Cush RheumNow ( View Tweet)

Cohort study shows ACE inhib. in Systemic Sclerosis at Dx was assoc w/ increased risk for Scleroderma Renal Crisis (SRC). Military System EHR study of 31 SRC to 332 non-SRC & found ACEi assoc w/ SRC (OR 4.1; CI 1.6–10.2) only in presence of proteinuria https://t.co/cMsheXrmRY

Links:

Dr. John Cush RheumNow ( View Tweet)

Is tea consumption associated with a risk of fractures? A metanalysis of 16 studies, 772,707 participants, high (compared to low) tea consumption was associated a lower fracture risk - RR 0.86 (0.78–0.94). https://t.co/24XYyUArS9

Links:

Dr. John Cush RheumNow ( View Tweet)

Billion dollar companies (J&J, Pfizer) legally sparing over Billion dollar drugs! FTC is investigating Remicade contracting practices. Pfizer (for Inflectra) asserts J&J violated antitrust laws, anticompetitive practices aimed to block Inflectra sales https://t.co/3yk4AcM5ZW

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA will review to Genentechs application for Rituxan use in pediatric (age >2yrs) granulomatosis with polyangiitis & microscopic polyangiitis. If approved, this would be the 1st pediatric indication for RTX; data based on ths phase IIa PePRS study https://t.co/rRFiyQNKca

Links:

Dr. John Cush RheumNow ( View Tweet)

Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY

Links:

Dr. John Cush RheumNow ( View Tweet)

Testosterone replacement therapy Increases the risk of CV events (MI/CVA/TIA). Study of 15,401 men, >45 yrs old, w/ low testosterone & no evidence of hypogonadotropic or testicular dz (1995-2017). HR 1.21; CI 1.0-1.46), highest in the 1st 2yrs https://t.co/nNXyFIo1EH

Links:

Dr. John Cush RheumNow ( View Tweet)

Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a negative opinion on Application for romosozumab (Evenity) for the treatment of severe osteoporosis (by Amgen & UCB); an appeal is planned https://t.co/EVjxuBQdF0

Links:

Dr. John Cush RheumNow ( View Tweet)

Im starting a War on RA. I need you go get mad and do your part. Read 1st of 4 part series https://t.co/sR5Z3lq8CU or watch it here https://t.co/s7CVW2dNUT

Links:

Dr. John Cush RheumNow ( View Tweet)

The FDA Arthritis Advisory Committee voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up! News, Announcements of generics/biosimilars, approvals and FDA hearings. Watch the video here>> https://t.co/3tW7uRivgQ or listen to the podcast on iTunes>> https://t.co/q2bscJkIhs

Links:

Dr. John Cush RheumNow ( View Tweet)

Image challenge: A 48-year-old man presented to the dermatology clinic with a 6-month history of painful hand ulcerations and shortness of breath. He has no muscle weakness or arthritis. What is the diagnosis? https://t.co/kQrNuVExlQ https://t.co/n3435OCPLA

Links:

NEJM NEJM ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×